Načítá se...
A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
INTRODUCTION: Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), approved for treatment of type 2 diabetes mellitus (T2DM). There is limited direct evidence comparing the efficacy and tolerability of exenatide 2 mg once weekly (QW) to other GLP-1 RAs. A network meta-analysis (NMA) w...
Uloženo v:
Vydáno v: | Diabetes Ther |
---|---|
Hlavní autoři: | , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Springer Healthcare
2016
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4801811/ https://ncbi.nlm.nih.gov/pubmed/26886440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-016-0155-1 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|